Expanding the Role of Suprachoroidal Injections - Takeaways - MDSpire

Expanding the Role of Suprachoroidal Injections

Clinical data support this targeted route for small molecules, gene therapy, and oncologic agents, with a good safety profile and potential to reduce treatment burden.

  • By

  • Thomas A. Ciulla, MD, MBA

  • September 1, 2025

  • 18 min

Share

  • 1

    Suprachoroidal injections offer targeted drug delivery to chorioretinal tissues, minimizing exposure to unaffected ocular structures.

  • 2

    The FDA approved Xipere for suprachoroidal use in treating uveitic macular edema, marking a significant advancement in ocular therapeutics.

  • 3

    Suprachoroidal drug delivery achieves durable drug levels in the retina while limiting adverse effects associated with anterior-segment exposure.

  • 4

    Innovative delivery systems, such as catheter-based and microneedle-based platforms, enhance patient convenience and expand access to treatments.

  • 5

    Recent clinical trials demonstrate the effectiveness of new technologies, including the Everads Injector and Orbit Subretinal Delivery System, for ocular therapies.

Original Source(s)

Expanding the Role of Suprachoroidal Injections

  • by Thomas A. Ciulla, MD, MBA

  • September 1, 2025

Related Content

Vamikibart Shows Early Safety in Uveitic Macular Edema

Phase 1 nonrandomized trial reported no drug-related serious adverse events, but efficacy remains unproven

Cell death in uveitis: pyroptosis, ferroptosis, apoptosis, and beyond

Myopia Severity Tied to Pediatric Retinal Pathology

Routine dilated examinations identified peripheral retinal abnormalities across refractive groups, with higher pathology rates among patients with at least 3.00 D of myopia